| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 8, 2003
From the Coronary Artery Disease Research Unit, Department of Cardiological Sciences, St George’s Hospital Medical School, London, UK (E.Z., S.F., J.C.K.); Hospital General Universitario Gregorio Marañón, Madrid, Spain (P.A.); and Hospital General Universitario, Guadalajara, Spain (R.A.-E.).
Background--Both endothelial cell activation and macrophage activation play a significant role in atherogenesis and atheromatous plaque vulnerability and may determine rapid coronary artery disease (CAD) progression. We sought to assess the association between serum inflammatory markers and rapid CAD progression in patients with chronic stable angina pectoris. Methods and Results--We studied 124 chronic stable angina pectoris patients (84 men; mean age, 61±10 years) who were on a waiting list for coronary angioplasty for a mean time of 4.8±2.4 months. CAD progression was defined as Conclusions--Rapid CAD progression in patients with stable angina pectoris is associated with increased C-reactive protein levels and raised concentrations of biochemical markers of endothelial and macrophage activation.
Revised on April 22, 2004
Accepted on May 21, 2004
Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris
Emmanouil Zouridakis MD,
10% diameter reduction of a pre-existing stenosis
50%,
30% diameter reduction of a stenosis <50%, development of a new stenosis
30% in a previously normal segment, or progression of any stenosis to total occlusion. CAD progression occurred in 35 patients (28%). After adjustment with binary logistic regression, neopterin (P<0.001), high-sensitivity C-reactive protein (P=0.017), matrix metalloproteinase-9 (P=0.002), soluble intercellular adhesion molecule 1 (P<0.001), and previous history of unstable angina (P=0.01) were independent predictors of rapid CAD progression. The association between rapid disease progression and inflammatory markers remained significant even when presence of complex lesions was introduced into the multivariate model.
Related Article:
Circulation 2004 110: 1709.
This article has been cited by other articles:
![]() |
P. Avanzas, R. Arroyo-Espliguero, and J. C. Kaski Neopterin and Cardiovascular Disease: Growing Evidence for a Role in Patient Risk Stratification Clin. Chem., June 1, 2009; 55(6): 1056 - 1057. [Full Text] [PDF] |
||||
![]() |
S. Agewall Acute and stable coronary heart disease: different risk factors Eur. Heart J., August 2, 2008; 29(16): 1927 - 1929. [Full Text] [PDF] |
||||
![]() |
T. J. Bunch, C. S. Rihal, R. J. Gumina, L. Cooper, and N. M. Caplice Progression of Nonculprit Plaque Stenosis Following Successful Percutaneous Intervention Angiology, May 1, 2008; 59(2): 236 - 239. [Abstract] [PDF] |
||||
![]() |
L. U. Zimmerli, E. Schiffer, P. Zurbig, D. M. Good, M. Kellmann, L. Mouls, A. R. Pitt, J. J. Coon, R. E. Schmieder, K. H. Peter, et al. Urinary Proteomic Biomarkers in Coronary Artery Disease Mol. Cell. Proteomics, February 1, 2008; 7(2): 290 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Brevetti, V. Schiano, E. Laurenzano, G. Giugliano, M. Petretta, F. Scopacasa, and M. Chiariello Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease Eur. Heart J., January 2, 2008; 29(2): 224 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Antoniades, C. Shirodaria, M. Crabtree, R. Rinze, N. Alp, C. Cunnington, J. Diesch, D. Tousoulis, C. Stefanadis, P. Leeson, et al. Altered Plasma Versus Vascular Biopterins in Human Atherosclerosis Reveal Relationships Between Endothelial Nitric Oxide Synthase Coupling, Endothelial Function, and Inflammation Circulation, December 11, 2007; 116(24): 2851 - 2859. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Adachi, T Naruko, A Itoh, R Komatsu, Y Abe, N Shirai, H Yamashita, S Ehara, M Nakagawa, C Kitabayashi, et al. Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions Heart, December 1, 2007; 93(12): 1537 - 1541. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Punjabi, B. A. Beamer, A. Jain, M. E. Spencer, and N. Fedarko Elevated Levels of Neopterin in Sleep-Disordered Breathing Chest, October 1, 2007; 132(4): 1124 - 1130. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Okura, H. Taguchi, T. Kubo, I. Toda, M. Yoshiyama, J. Yoshikawa, and K. Yoshida Impact of arterial remodelling and plaque rupture on target and non-target lesion revascularisation after stent implantation in patients with acute coronary syndrome: an intravascular ultrasound study Heart, October 1, 2007; 93(10): 1219 - 1225. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Ray, D. A. Morrow, M. S. Sabatine, A. Shui, N. Rifai, C. P. Cannon, and E. Braunwald Long-Term Prognostic Value of Neopterin: A Novel Marker of Monocyte Activation in Patients With Acute Coronary Syndrome Circulation, June 19, 2007; 115(24): 3071 - 3078. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Arbustini Total Erythrocyte Membrane Cholesterol: An Innocent New Marker or an Active Player in Acute Coronary Syndromes? J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2090 - 2092. [Full Text] [PDF] |
||||
![]() |
S. Waxman, F. Ishibashi, and J. E. Muller Detection and Treatment of Vulnerable Plaques and Vulnerable Patients: Novel Approaches to Prevention of Coronary Events Circulation, November 28, 2006; 114(22): 2390 - 2411. [Full Text] [PDF] |
||||
![]() |
D. S. Berman, R. Hachamovitch, L. J. Shaw, J. D. Friedman, S. W. Hayes, L. E.J. Thomson, D. S. Fieno, G. Germano, N. D. Wong, X. Kang, et al. Roles of Nuclear Cardiology, Cardiac Computed Tomography, and Cardiac Magnetic Resonance: Noninvasive Risk Stratification and a Conceptual Framework for the Selection of Noninvasive Imaging Tests in Patients with Known or Suspected Coronary Artery Disease J. Nucl. Med., July 1, 2006; 47(7): 1107 - 1118. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Aboyans, M. H. Criqui, J. O. Denenberg, J. D. Knoke, P. M Ridker, and A. Fronek Risk Factors for Progression of Peripheral Arterial Disease in Large and Small Vessels Circulation, June 6, 2006; 113(22): 2623 - 2629. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Winkler, F. Ueberall, and D. Fuchs In vitro testing for antiinflammatory properties of compounds. Clin. Chem., June 1, 2006; 52(6): 1201 - 1202. [Full Text] [PDF] |
||||
![]() |
K. K. Koh, S. H. Han, and M. J. Quon Inflammatory Markers and the Metabolic Syndrome: Insights From Therapeutic Interventions J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1978 - 1985. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Abrams and U. Thadani Therapy of Stable Angina Pectoris: The Uncomplicated Patient Circulation, October 11, 2005; 112(15): e255 - e259. [Full Text] [PDF] |
||||
![]() |
J. C. Kaski, P. Avanzas, and R. Arroyo-Espliguero Neopterin: Still a Forgotten Biomarker Clin. Chem., October 1, 2005; 51(10): 1902 - 1903. [Full Text] [PDF] |
||||
![]() |
J. Abrams Chronic Stable Angina N. Engl. J. Med., June 16, 2005; 352(24): 2524 - 2533. [Full Text] [PDF] |
||||
![]() |
J. C. Kaski, P. Avanzas, R. Arroyo-Espliguero, and B. S. Coller Neutrophil Count and Complex Lesions in Patients With Coronary Artery Disease Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): e112 - e112. [Full Text] [PDF] |
||||
![]() |
P. Avanzas, R. Arroyo-Espliguero, J. Quiles, D. Roy, and J. C. Kaski Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris Eur. Heart J., March 1, 2005; 26(5): 457 - 463. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |